Tugba Bagcı-Önder

1.7k total citations · 1 hit paper
43 papers, 1.1k citations indexed

About

Tugba Bagcı-Önder is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Tugba Bagcı-Önder has authored 43 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 8 papers in Genetics and 8 papers in Oncology. Recurrent topics in Tugba Bagcı-Önder's work include Glioma Diagnosis and Treatment (8 papers), RNA Interference and Gene Delivery (7 papers) and Cell death mechanisms and regulation (7 papers). Tugba Bagcı-Önder is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), RNA Interference and Gene Delivery (7 papers) and Cell death mechanisms and regulation (7 papers). Tugba Bagcı-Önder collaborates with scholars based in Türkiye, United States and United Kingdom. Tugba Bagcı-Önder's co-authors include Fidan Seker-Polat, Khalid Shah, Ahmet Cingöz, İhsan Solaroğlu, Hiroaki Wakimoto, Alişan Kayabölen, Daniel G. Jay, Seda Kızılel, Pelin Erkoc and Junfeng Wu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Brain.

In The Last Decade

Tugba Bagcı-Önder

41 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives

2022 121 citations Fidan Seker-Polat, İhsan Solaroğlu et al. Cancers profile →

Peers

Countries citing papers authored by Tugba Bagcı-Önder

Since Specialization

Citations

This map shows the geographic impact of Tugba Bagcı-Önder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tugba Bagcı-Önder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tugba Bagcı-Önder more than expected).

Fields of papers citing papers by Tugba Bagcı-Önder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tugba Bagcı-Önder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tugba Bagcı-Önder. The network helps show where Tugba Bagcı-Önder may publish in the future.

Co-authorship network of co-authors of Tugba Bagcı-Önder

This figure shows the co-authorship network connecting the top 25 collaborators of Tugba Bagcı-Önder. A scholar is included among the top collaborators of Tugba Bagcı-Önder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tugba Bagcı-Önder. Tugba Bagcı-Önder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exploiting epigenetic targets to overcome taxane resistance in prostate cancer 2024 ·Cell Death and Disease ·Buse Cevatemre, (unknown), (unknown), (unknown), (unknown), (unknown), Tugba Bagcı-Önder, Ceyda Açılan	10
2	Directing chemiluminescent dioxetanes to mitochondria: A cationic luminophore enables in vitro and in vivo detection of cancer cells upon enzymatic activation 2023 ·Sensors and Actuators B Chemical ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ahmet Cingöz, (unknown), Tugba Bagcı-Önder, Safacan Kölemen	10
3	3D bioprinted glioma models 2022 ·PubMed ·Defne Yigci, Misagh Rezapour Sarabi, (unknown), (unknown), Emel Sokullu, Tugba Bagcı-Önder, Savaş Taşoğlu	20
4	Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives breakdown → 2022 ·Cancers ·Fidan Seker-Polat, (unknown), İhsan Solaroğlu, Tugba Bagcı-Önder	121
5	Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia 2022 ·International Journal of Molecular Sciences ·(unknown), İlknur Sur‐Erdem, (unknown), Yasemin Bölükbaşı, Uğur Selek, İhsan Solaroğlu, Tugba Bagcı-Önder	3
6	EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities 2022 ·Cell Death and Disease ·(unknown), (unknown), Alişan Kayabölen, (unknown), (unknown), Ahmet Cingöz, (unknown), (unknown), (unknown), (unknown), Tunç Morova, (unknown), (unknown), Martin Philpott, Adam P. Cribbs, Sonia H.Y. Kung, Nathan A. Lack, Tamer T. Önder, Tugba Bagcı-Önder	12
7	Glioma-on-a-Chip Models 2021 ·Micromachines ·(unknown), Sajjad Rahmani Dabbagh, (unknown), Tugba Bagcı-Önder, Savaş Taşoğlu	28
8	Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization 2021 ·Oncogene ·Ahmet Cingöz, (unknown), Tunç Morova, Fidan Seker-Polat, Myvizhi Esai Selvan, Zeynep H. Gümüş, Deepak Bhere, Khalid Shah, İhsan Solaroğlu, Tugba Bagcı-Önder	9
9	Identification of SERPINE1 as a Regulator of Glioblastoma Cell Dispersal with Transcriptome Profiling 2019 ·Cancers ·Fidan Seker-Polat, Ahmet Cingöz, İlknur Sur‐Erdem, (unknown), (unknown), (unknown), Myvizhi Esai Selvan, Zeynep H. Gümüş, Mehmet Gönen, Halil Bayraktar, Hiroaki Wakimoto, Tugba Bagcı-Önder	46
10	The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma 2019 ·Cell Death and Disease ·(unknown), İlknur Sur‐Erdem, Fidan Seker-Polat, Ahmet Cingöz, Alişan Kayabölen, (unknown), (unknown), (unknown), (unknown), Batu Erman, Mehmet Gönen, James E. Dunford, Udo Oppermann, Tugba Bagcı-Önder	26
11	May iron(III) complexes containing phenanthroline derivatives as ligands be prospective anticancer agents? 2019 ·European Journal of Medicinal Chemistry ·Cristina P. Matos, Zelal Adıgüzel, (unknown), Buse Cevatemre, Tugba Bagcı-Önder, Özge Çevik, Patrique Nunes, Liliana P. Ferreira, Maria Deus Carvalho, Débora L. Campos, Fernando R. Pavan, João Costa Pessoa, M. Helena García, Ana Isabel Tomaz, Isabel Correia, Ceyda Açılan	38
12	Experimental data on novel Fe(III)-complexes containing phenanthroline derivatives for their anticancer properties 2019 ·SHILAP Revista de lepidopterología ·Cristina P. Matos, Zelal Adıgüzel, (unknown), Buse Cevatemre, Tugba Bagcı-Önder, Özge Çevik, Patrique Nunes, Liliana P. Ferreira, Maria Deus Carvalho, Débora L. Campos, Fernando R. Pavan, João Costa Pessoa, M. Helena García, Ana Isabel Tomaz, Isabel Correia, Ceyda Açılan	2
13	Assessment of the MRI and behavioral test results in focal cerebral ischemia reperfusion model in rat after separate and combined use of mouse-derived neural progenitor cells, human-derived neural progenitor cells and atorvastatin 2017 ·Turkish Neurosurgery ·(unknown), Nail İzgi, Tugba Bagcı-Önder, Ece Erdağ, Yavuz Aras, (unknown)	4
14	An exploration of plastic deformation dependence of cell viability and adhesion in metallic implant materials 2016 ·Journal of the mechanical behavior of biomedical materials ·(unknown), (unknown), Ahmet Cingöz, Tugba Bagcı-Önder, Gregory Gerstein, Hans Jürgen Maier, D. Canadinç	22
15	Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme 2016 ·Cancer Biology & Therapy ·(unknown), Ahmet Cingöz, Ezgi Kaya-Aksoy, Selena Kazancioglu, Nathan A. Lack, Ceyda Açılan, Tugba Bagcı-Önder	31
16	Derivation of Neural Stem Cells from Mouse Induced Pluripotent Stem Cells 2015 ·Methods in molecular biology ·(unknown), Tugba Bagcı-Önder	3
17	Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors 2012 ·Oncogene ·Tugba Bagcı-Önder, (unknown), Deborah A. Flusberg, (unknown), Peter K. Sorger, Khalid Shah	36
18	Identification of CD44 as a Surface Biomarker for Drug Resistance by Surface Proteome Signature Technology 2011 ·Molecular Cancer Research ·(unknown), Robert Hauptschein, Jean K. Stewart, Tugba Bagcı-Önder, G G Sahagian, Daniel G. Jay	33
19	A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell–Delivered TRAIL in Experimental Glioma Models 2010 ·Cancer Research ·Tugba Bagcı-Önder, Hiroaki Wakimoto, Maarten Anderegg, (unknown), Khalid Shah	88
20	Autocrine semaphorin 3A signaling promotes glioblastoma dispersal 2009 ·Oncogene ·Tugba Bagcı-Önder, Junfeng Wu, Rolf Pfannl, Leodevico L. Ilag, Daniel G. Jay	96

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact